A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Recruiting
The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/21/2025
Locations: Research Site, Quilmes, Buenos Aires +80 locations
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
The study will evaluate the efficacy and safety of axatilimab in participants with IPF.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/21/2025
Locations: Royal Prince Alfred Hospital, Camperdown, New South Wales +73 locations
Conditions: Idiopathic Pulmonary Fibrosis
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
Recruiting
The primary objective of this study is to evaluate the long-term safety of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in other clinical studies of mRNA-3705.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
08/21/2025
Locations: UCLA Medical Center, Los Angeles, California +11 locations
Conditions: Methylmalonic Acidemia
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Recruiting
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: University of California, Los Angeles, Santa Monica, California +13 locations
Conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Recruiting
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +89 locations
Conditions: High-risk Large B-cell Lymphoma (LBCL)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
08/20/2025
Locations: Research Site, Athens, Alabama +908 locations
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Recruiting
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/20/2025
Locations: Sansum Clinic, Santa Barbara, California +371 locations
Conditions: Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/20/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +534 locations
Conditions: Progressive Pulmonary Fibrosis
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Recruiting
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will... Read More
Gender:
ALL
Ages:
Between 16 years and 69 years
Trial Updated:
08/20/2025
Locations: Stanford University - (Stanford Cancer Institute), Stanford, California +61 locations
Conditions: Hodgkin Lymphoma
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St, Gilbert, Arizona +52 locations
Conditions: Sjögren's Syndrome
Use of Passive Myofunctional Appliances for Snoring and Mild Obstructive Sleep Apnea
Recruiting
It is unknown whether passive myofunctional appliances can be used for the treatment of obstructive sleep apnea and snoring, nor how to select the appropriate size per individual patient. Exploring the possibility of using passive myofunctional appliances as a treatment option for patients with mild obstructive sleep apnea and/or snoring should be considered, especially as the time to fabricate and deliver custom designed dental sleep appliances can be significant (sometimes over a month). Use o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Enjoy Dental, Edmonton, Alberta
Conditions: Sleep Apnea, Obstructive
Cirrhosis Care Alberta (CCAB): A Pragmatic Type II Hybrid Effectiveness Implementation Trial
Recruiting
Liver cirrhosis is the leading cause of morbidity and premature mortality in patients with digestive disease. There are many gaps in care which contribute to a high rate of hospital readmissions (44 percent at 90 days) and inadequate quality of care. Currently, there is a lack of structured processes to initiate best practice support for medical and broader health needs of high risk patients. The cirrhosis care Alberta program (CCAB) is a 3 year multi-component quality improvement initiative wh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: University of Alberta, Edmonton, Alberta
Conditions: Cirrhosis, Liver